1
Clinical Trials associated with MOv-PBL vaccine(National Cancer Institute)TREATMENT OF PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER USING ANTI-CD3 STIMULATED PERIPHERAL BLOOD LYMPHOCYTES TRANSDUCED WITH A GENE ENCODING A CHIMERIC T-CELL RECEPTOR REACTIVE WITH FOLATE BINDING PROTEIN
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer.
PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white blood cells in treating patients who have advanced ovarian epithelial cancer.
100 Clinical Results associated with MOv-PBL vaccine(National Cancer Institute)
100 Translational Medicine associated with MOv-PBL vaccine(National Cancer Institute)
100 Patents (Medical) associated with MOv-PBL vaccine(National Cancer Institute)
100 Deals associated with MOv-PBL vaccine(National Cancer Institute)